Abstract

BackgroundThe ultimate goal for Rheumatoid Arthritis (RA) management is the simultaneous achievement of all clinical, functional and structural efficacy, i.e. comprehensive disease control (CDC) [1].ObjectivesTo evaluate the effective chance and...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
SAT0085 A MATRIX RISK MODEL FOR PREDICTING 5-YEAR RADIOGRAPHIC PROGRESSION IN A COHORT OF EARLY RHEUMATOID ARTHRITIS TREATED ACCORDING TO T2T STRATEGY
Luca Petricca ... Dario Bruno
-
Luca Petricca, et. al.Luca Petricca ... Dario Bruno
01 Jun 2019
AB0244 THE IMPORTANCE OF TREATMENT STRATEGY FOR THE OUTCOME OF EARLY RHEUMATOID ARTHRITIS PATIENTS NOT RESPONDERS TO THE FIRST LINE THERAPY WITH METHOTREXATE
Luca Petricca ... Dario Bruno
-
Luca Petricca, et. al.Luca Petricca ... Dario Bruno
01 Jun 2019
POS0662 BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS PRESCRIPTION OVER TIME IN A COHORT OF EARLY RHEUMATOID ARTHRITIS PATIENTS
R La Ferrara ... A L Fedele
-
R La Ferrara, et. al.R La Ferrara ... A L Fedele
23 May 2022
FRI0151 The Association between Age and Inflammatory Findings on Hand and Foot MRI in Early Arthritis, Rheumatoid Arthritis and Symptom-Free Controls
L Mangnus ... W.P Nieuwenhuis
Annals of the Rheumatic Diseases | VOL. 75
L Mangnus, et. al.L Mangnus ... W.P Nieuwenhuis
01 Jun 2016
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers